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Chemical regulation is challenged by the large number of chemicals requiring assessment for potential
human health and environmental impacts. Current approaches are too resource intensive in terms of
time, money and animal use to evaluate all chemicals under development or already on the market.
The need for timely and robust decision making demands that regulatory toxicity testing becomes more
cost-effective and efficient. One way to realize this goal is by being more strategic in directing testing
resources; focusing on chemicals of highest concern, limiting testing to the most probable hazards, or tar-
geting the most vulnerable species. Hypothesis driven Integrated Approaches to Testing and Assessment
(IATA) have been proposed as practical solutions to such strategic testing. In parallel, the development of
the Adverse Outcome Pathway (AOP) framework, which provides information on the causal links
between a molecular initiating event (MIE), intermediate key events (KEs) and an adverse outcome
(AO) of regulatory concern, offers the biological context to facilitate development of IATA for regulatory
decision making. This manuscript summarizes discussions at the Workshop entitled ‘‘Advancing AOPs for
Integrated Toxicology and Regulatory Applications’’ with particular focus on the role AOPs play in inform-
ing the development of IATA for different regulatory purposes.
 2014 Elsevier Inc. All rights reserved.1. Introduction
1.1. AOPs to support IATA in regulatory decision-making
Within the last decade, the global economy has witnessed a
significant shift in the regulatory environment coupled with the
volume and diversity of industrial chemicals being manufactured.Despite some regional differences, regulatory management in gen-
eral comprises hazard identification/characterization, an exposure
assessment and a risk assessment as its main steps. In some cases,
the identification of hazards is prior to market approval and certain
hazards e.g. carcinogenicity (C), mutagenicity (M), or reproductive
(R) effects (CMRs) may lead to restrictions on use irrespective of
any subsequent risk assessment.
The hazard identification step is driven by a desire to identify all
the hazards of potential concern and assign the appropriate hazard
classification (i.e. classification and labelling requirements) regard-
less of the relevance of these hazards as a consequence of expo-
sure. The hazard characterization step is often associated with
extensive in vivo toxicity testing using standardized guidelines or
protocols. The time, cost and animal use to generate such hazard
data are significant and difficult to achieve in practice given the
1 Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA).
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the classical in vivo testing approach is based on apical endpoints,
which typically provide minimal information on the mode or
mechanism of action. This limits the development and application
of new in vitro assays, read-across approaches or inter-species
extrapolation, all of which could facilitate an initial hazard assess-
ment. In addition, the societal demand to use (vertebrate) animal
tests only as a last resort for obtaining hazard information coupled
with the increasing number of different regulatory programs
worldwide calls for a re-consideration of traditional assessment
strategies and incorporation of alternative approaches. At the same
time, substantial advances have been made in the use of high
throughput (HT) and high content (HC) screening assays to
quantify and characterize molecular and cellular responses to
chemicals (Kavlock et al., 2007; Judson et al., 2014; Kleinstreuer
et al., 2014). A shift towards more mechanistically-based alterna-
tive approaches represents a promising opportunity for assessing
hazards of regulatory concern. To that end the Adverse Outcome
Pathway (AOP) framework provides the biological context and sup-
porting weight of evidence (WoE) to facilitate the interpretation of
such alternative data. An AOP represents the existing knowledge
concerning the causal linkages between the molecular initiating
event (MIE) and the cascade of intermediate or key events (KEs)
at the subcellular, cellular, tissue and organ level that lead to a spe-
cific adverse outcome (AO) at the individual or population level
(Ankley et al., 2010; OECD, 2013). This conceptual framework
enables information and data from different chemicals, different
levels of biological organization, and different taxonomic domains
relevant for one AOP to be assembled. Well-developed AOPs may
therefore be expected to help guide identification of experimental
testing (e.g. in vivo, in vitro, in chemico) and non-testing (in silico)
approaches to support regulatory decision making. There is now
a need for an objective framework to interpret the results from
novel test methods and their prediction models in order to
facilitate their application in regulatory decision making. Such a
framework will conceivably consist of three main elements: the
AOP itself, non-animal (alternative) test methods and in silico
approaches targeting key components of the AOP, and their
associated prediction models for a particular regulatory context.
The synthesis and integration of these elements form the basis
for developing Integrated Approaches to Testing and Assessment
(IATA) that may be used in regulatory applications.
This manuscript summarizes discussions from the Workshop
entitled ‘‘Advancing AOPs for Integrated Toxicology and Regulatory
Applications’’ held in Somma Lombardo, Italy on the 2–7th March,
2014 (https://aopkb.org/saop/workshops/somma.html). Specifi-
cally it captures the discussions and insights derived within the
workgroup that discussed the role that AOPs can play in informing
the development of IATA for regulatory purposes. The next section
defines IATA and related terms. Following that, the main elements
or components that make up IATA are described including consid-
erations, (e.g. scientific confidence), that are associated with these
different elements and their integration. Once the components
have been defined, the overall applicability and limitations of IATA
for different regulatory purposes are considered. These concepts
are then illustrated by way of three examples that are supported
by specific AOPs at different levels of development. A final sum-
mary considers how the proposed conceptual framework may
impact different regulatory applications.
2. IATA and related concepts
Integrated Approaches to Testing and Assessment (IATA) are
structured approaches that integrate and weigh different types of
data for the purposes of performing hazard identification (i.e. the
potential to cause a hazard), hazard characterization (e.g. the toxicpotency) and/or safety assessment (i.e. the potential/toxicity
potency related to exposure) of a chemical or group of chemicals.
For the purposes of this paper, IATA will be generally referred to
in a singular form to represent a specific case rather than a collec-
tive approach. An IATA should be viewed as an iterative process
that includes efficiency analyses to determine whether more data,
and what type of data, are required to make effective regulatory
decisions while reducing reliance on animal testing. An IATA is
not a novel concept per se, indeed it has been discussed at a special
OECD workshop on IATA in 2007 (OECD, 2008) and described by
the US EPA as part of a FIFRA1 Scientific Advisory Panel document
in 2011 (US EPA, 2011).
An IATA initially gathers and weighs relevant existing informa-
tion to derive an initial conclusion. If the existing information is
insufficient to address the regulatory or safety decision under
consideration, it guides the generation of new data using a hypoth-
esis-driven approach with the goal of addressing the residual
uncertainty preventing a regulatory decision. The benefit of an
IATA lies in the potential breadth of information that can be used
in the assessment, as it may exploit both non-testing (in silico)
and experimental (in vivo, in vitro and in chemico) approaches.
The IATA is considered a generic approach and may encompass
testing strategies such as integrated testing strategies (ITS),
sequential testing strategies (STS), as well as weight of evidence
(WoE) considerations (OECD, 2014a). Both ITS, i.e. the fixed and
structured integration and weighing of relevant information to
support the final decision (Ahlers et al., 2008; Hartung et al.,
2013a,b), and STS, i.e. the fixed stepwise approach involving
interim decision steps to reach a decision, represent structured
and formal processes to derive a conclusion (OECD, 2014a). In con-
trast, WoE considerations, i.e. the structured, systematic, indepen-
dent and transparent review of existing and available data without
the use of experimental or computational efforts, aim to perform a
reliable and relevant compilation of knowledge intended for a cer-
tain regulatory purpose (Balls et al., 2006; OECD, 2014a). Whilst an
IATA provides a structure for data integration and a means for tar-
geting testing for particular uses, it is not necessarily framed by
any mechanistic rationale. There is growing support for using AOPs
to provide such a mechanistic basis (OECD, 2013). Thus, AOP-
informed IATA development may drive the development of in silico,
in vitro, or in chemico approaches that are anchored in well-
developed knowledge as captured within an AOP. Exposure consid-
erations and the use of exposure assessment tools may also form
an integral part of an IATA.
AOPs are expected to provide insight into the biological rele-
vance, reliability, and uncertainties associated with the results
from in silico, in chemico and in vitro approaches for regulatory
use. AOPs also have substantial merit over traditional assessment
strategies. For instance, they can assist manufacturers and regula-
tors to identify whether a potential hazard can be expected that
justifies subsequent detailed testing. Furthermore, in environmen-
tal hazard and risk assessment, they show great promise in
species-to-species extrapolation critical for protection of endangered
species (Perkins et al., 2013). AOPs could also help to design ITS,
which ideally cover the relevant key events of an AOP. AOPs are
intended to provide a transparent evaluation of available evidence
and relevant data, scientific confidence is envisioned to be evalu-
ated through approaches akin to the ‘‘Bradford Hill Considerations’’
developed originally in epidemiology (Hill, 1965; OECD, 2013).
Briefly, by examining: (1) biological concordance, (2) essentiality
of Key Events, (3) concordance of empirical observation (encom-
passes dose response and temporal concordance and beyond), (4)
consistency (among different biological contexts) and (5) analogy
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supporting evidence for the AOP can be developed (Meek et al.,
2014a,b). Depending on the outcomes for these considerations, a
given AOP may differ in its level of scientific rigor and confidence,
which in turn will drive its practical suitability in addressing differ-
ent regulatory applications (Perkins et al., submitted; Patlewicz
et al., submitted).
The practical implementation of an AOP-informed IATA for a
given chemical or group of chemicals considers problem formula-
tion based on the risk management scope and goals, the selection
and evaluation of suitable AOPs to inform the IATA and existing
information that is available for the chemical(s) of interest. All
these considerations will influence the makeup of an IATA in terms
of the different types of testing (e.g. in chemico, in vitro and in vivo),
non-testing (e.g. in silico), or data integration approaches (e.g. ITS,
STS, WoE or other IATA strategies) that can be exploited (Fig. 1.).
Fig. 1 outlines a proposed framework to guide how existing infor-
mation (e.g. hazard and exposure information) needs to be evalu-
ated and what new data, if any, needs to be generated, so that
the IATA can lead to a regulatory decision.3. Elements for developing AOP-informed IATA
Non-testing and testing approaches as well as data integration
strategies form the elements or building blocks that are necessary
to derive IATA. These elements are described in more detail in
terms of the applicability and limitations in the following sections.
3.1. Non-testing approaches
Non-testing or in silico approaches serve two functions within
an IATA, they either provide a way to organize existing information
or they are used to make predictions of molecular initiating events
(MIE) or other key events (KEs) as defined in an associated AOP.
The breadth of non-testing approaches is extensive. They range
from the search and retrieval of existing data, to the identificationFig. 1. Conceptual framework for an AOP-informed IATA to support regulatory dec
consideration of the risk management scope, the data requirements and the level of
application will also provide an indication of the level of AOP confidence, ideally need
approaches, etc.), will evaluate the existing information that is available for the chemica
AOP itself (b), and other relevant information that is pertinent in making a regulatory deci
for the regulatory purpose of interest, no further action is warranted. If the outcome deriv
to be generated through new testing and assessment. The new information derived will th
could result in more thorough regulatory follow up or implementation of measures to
augment the corresponding AOP.of structural fragments to indicate activity and assist grouping (e.g.
structure–activity relationships (SARs), read-across), to quantita-
tive models (e.g. quantitative structure–activity relationships
(QSARs). Some of these SARs or QSARs may be housed in software
tools known as expert systems for ease of use. A summary of non-
testing approaches that may be useful in the development of IATA
are described in more detail in Cronin and Madden (2010).
Within IATA, non-testing approaches will most likely be
exploited to characterize the MIE within AOPs either qualitatively
or quantitatively (Table 1). A number of different types of MIEs,
and thus AOPs, may be identified for a given IATA in order to gen-
erate sufficient information for the decision to be made.3.1.1. Confidence factors for in silico models in IATA
Assuring scientific confidence in the validity of in silico models
and their outcomes are key considerations for their application.
For (Q)SARs, the OECD has developed validation principles which
provide a framework for assuring the scientific validity (relevance
and reliability) of a (Q)SAR model (OECD, 2004, 2007). The (Q)SAR
model reliability is a relative concept, depending on the context in
which the model is applied; meeting each and all of the OECD prin-
ciples is not necessarily warranted. It is worth noting that the
OECD principles only focus on the scientific validity of a given
(Q)SAR model, and not on the prediction it generates. The ade-
quacy of a (Q)SAR result for a given compound also needs to be
considered before use. In the context of the European Regulation
for Registration, Evaluation, Authorisation and restriction of
CHemicals (REACH) (EC, 2006; ECHA, 2008) the following specific
conditions are considered when evaluating in silico models:
1. the estimate should be generated by a valid (relevant and reli-
able) model;
2. the model should be applicable to the chemical of interest with
the necessary level of reliability;
3. the model endpoint should be relevant for the regulatory
purpose.isions. The framework is driven by the problem formulation, which involves a
acceptable uncertainty associated with the decision being made. The regulatory
ed. The framework, which comprises different elements (testing and non-testing
l(s) of interest (a), the type of information that might be required as defined by the
sion (c). If the outcome generated based on the framework is of sufficient confidence
ed from the framework is of insufficient confidence, then additional data might need
en be passed back into the framework for re-evaluation. Indeed a decision outcome
reduce use and/or exposure. Any new information generated will also be used to
Table 1
Examples of MIEs within AOPs that may be relevant to IATA endpoints derived from non-testing approaches.
MIE Effect Examples of in silico tool(s)
Unspecific – no definable single
molecular site of action
General accumulation in cellular membranes leading to
e.g. narcosis, basal cytotoxicity etc
Classification schemes e.g. Verhaar implemented in the OECD
QSAR Toolbox or Toxtree. QSARs based on hydrophobicity
Non-specific covalent binding (and
formation of radicals)
Irreversible binding to cellular protein and/or DNA
which may lead to a variety of effects; e.g. fibrosis
OECD QSAR Toolbox profilers for protein and DNA binding.
Quantum chemical calculations
Redox cycling leading to disruption of
specific pathways
Mitochondrial toxicity Structural alerts e.g. Nelms et al., in press
Receptor mediated effects on
signalling pathways
A wide variety of acute and non-lethal effects e.g.
estrogen receptor binding
3-D molecular modelling. Toxicophores/alerts e.g. EPA ER
binding expert system as encoded in the OECD QSAR Toolbox,
DART system (Wu et al., 2013)
Physical effects Skin corrosion Structural alerts, physicochemical properties e.g. pH
Unknown or very poorly defined MIE Idiosyncratic drug toxicity Structural alerts
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tions could be conceivably adapted to address other regulatory
purposes.
For chemical categorization (OECD, 2014b) (e.g. read-across), no
such principles have been formalized. Systematic frameworks to
aid in the evaluation of read-across and identify associated uncer-
tainties are in development by European Chemicals Agency (ECHA)
(known as the Read-Across Assessment Framework (RAAF)) as well
as by Industry (Blackburn and Stuard, 2014). To date these
frameworks do not specifically consider the role of AOPs or how
alternative data characterizing MIEs or other KEs may be conceiv-
ably used to address uncertainties. Work underway within the
SEURAT program (ChemWatch, 2014 – see: http://chemical-
watch.com/19594/seurat-1-homes-in-on-test-chemicals-for-read-
across) and independently by DECO-2, a Cefic-LRI AIMT-4 project
(Patlewicz et al., in preparation) are both aiming to investigate
the feasibility of enhancing read-across by using the AOP concept.
It is noteworthy to mention that there will be clear instances
when in silico approaches will not provide meaningful information
in the context of an IATA, for example if there is no direct linkage to
the MIE because the MIE is unknown or ill-defined. Predictions
from in silico approaches will also be inappropriate, when the tar-
get substance is outside of the applicability domain of the model.
3.2. Testing approaches
There are many testing approaches that can form key elements
within an IATA – from in chemico, in vitro to in vivo experimental
efforts. Testing elements such as toxicogenomics, high content/
high-throughput screening (HC/HT) in particular will play a crucial
role in shifting IATA away from a reliance on in vivo information
addressing one or multiple adverse outcomes.
3.2.1. In chemico tests
Biological effects of chemicals can be provoked by an initial
covalent modification of a biological macromolecule. The covalent
modification of DNA leading to mutagenesis or the reaction with
immunoproteins resulting in immunosuppression represent prom-
inent examples (Cronin et al., 2009). In chemico tests are experi-
mental measurements that address these covalent modifications
without involving biological organisms (reviewed in Schwöbel
et al., 2011). These assays are usually used to identify, and in some
cases estimate, the intrinsic reactivity of substances to a specific
biological target and in that respect are best suited to target the
MIE within an AOP. Most in chemico tests relevant to toxicity pre-
diction have investigated the reaction of an electrophilic molecule
(normally assumed to be the toxicant) with a model nucleophile
(representing a surrogate for the target biological macromolecule)
(e.g. Roberts et al., 2008; Aptula and Roberts, 2006; Schultz et al.,
2005; Thaens et al., 2012). Also included in this type of data could
be the assessment of oxidizing behavior and the role of otherreactive species (nucleophiles, reactive oxygen species, radicals)
principally amenable to in chemico testing (Cronin et al., 2009).
3.2.2. In vitro and alternative test systems
Cellular in vitro systems, lower vertebrate embryos and inverte-
brates are proposed and used as alternative test systems to
indicate toxic potential to various organisms. Relevant information
on the toxic potential of a chemical can be obtained via e.g.
comparison of the toxicity to baseline toxicity as an indicator
of a non-narcotic or specific mode of action (Escher and
Schwarzenbach, 2002). By including appropriate endpoints, it is
possible to target MIEs or KEs relevant for an AOP-informed assess-
ment. Extrapolations from alternative test systems, however, have
to consider that the toxicokinetic properties may greatly differ and
result in deviating effect concentrations between e.g. in vitro and
in vivo tests. Fish/amphibian embryos or invertebrates – despite
their evolutionary distance to e.g. mammalians or other vertebrate
classes – may provide in some cases a higher predictive capacity
than in vitro systems given that they represent/accommodate the
complexity of a whole organism (Perkins et al., 2013).
3.2.3. High throughput screening assays
High throughput screening assays (HT) comprise in chemico and
certain in vitro test methods such as receptor binding or receptor
transactivation assays (Romanov et al., 2008), cellular reporter
assays (Romanov et al., 2008; Kleinstreuer et al., 2014), assays
using invertebrate (e.g. Caenorhabditis elegans, Drosophila, algae,
crustaceans, see Perkins et al., 2013) or fish embryos (Truong
et al., 2014). Toxicogenomic (transcriptomics, proteomics, and
metabolomics), utilizing non-biased screening approaches may
play a more important role in the future within IATA, since they
allow more detailed insights into mechanisms of action and can
be applied to survey the breadth of molecular/cellular effects rele-
vant for a wide variety of AOPs (Garcia-Reyero et al., 2014a,b).
Assays targeted towards MIEs, can be very specific for a distinct
target (e.g., receptor, enzyme) that leads to an AO. This specificity
will also provide the chemical structure and bioactivity data
needed to foster development of in silico models (as described in
Section 3.1). Assays that target downstream KEs such as more gen-
eric stress responses (Simmons et al., 2009) may not have this
specificity, but may provide an approach to integrate multiple MIEs
(Miller et al., 2009). More importantly, analysis of downstream KEs
provide the opportunity to predict an AO even in cases where the
precise MIE is not known or is not fully understood. Table 2 pre-
sents several examples of alternative experimental testing
approaches that may be relevant to predict AOs within an IATA.
3.2.4. Confidence factors and limitations for testing approaches in IATA
The use of alternative testing approaches provide higher confi-
dence when they are scientifically and technically valid for use.
Validation of alternative assays in particular HT/HC assays has
K.E. Tollefsen et al. / Regulatory Toxicology and Pharmacology 70 (2014) 629–640 633been subject of several publications such as Judson et al. (2013),
Hartung et al. (2013a,b), Patlewicz et al. (2013). In the latter,
scientific confidence was discussed in the context of the existing
validation frameworks for (Q)SARs and biomarkers (Institute of
Medicine, 2010). In Cox et al. (2014), a scientific confidence
framework was proposed comprising three inter-related elements
to facilitate the systematic, transparent and objective evaluation
and documentation of HT/HC assays and their associated predic-
tion models. The elements comprise analytical validation, qualifi-
cation and utilization. Analytical validation would entail an
assessment of the biological basis and analytical performance of
the assays. This would involve a consideration of what events
within the AOP the assay(s) were mapped to – whether they target
the MIE or other downstream KEs. The applicability domain of the
assay in terms of the chemical coverage and the typical perfor-
mance statistics – sensitivity, specificity, accuracy, would be
considered as well. The qualification step would involve an assess-
ment of the associated prediction models derived from such assays
and utilization would consider the intended regulatory application
based on the previous 2 steps.
Even when assays have been scientifically and technically vali-
dated, theymay exhibit certain limitations. Most assays do not con-
sider the impact of potential metabolic transformation, which can
lead to reduced sensitivity (in case of in vivo metabolic activation)
or to a high number of false positives (in case of in vivo inactivation)
or false negatives (in case of in vivo bioactivation). Furthermore, cer-
tain compounds are difficult or impossible to test using in vitro sys-
tems, for example due to their poor solubility in the culturemedium,
aggregation potential, volatility, or partitioning behavior (tendency
to adsorb onto plastic). In such cases in silicomethods could provide
a more appropriate approach (Zaldivar et al., 2010, 2011).
3.3. Data-integration strategies
Whilst there has been a tendency to define one ‘‘definitive’’ test
for hazard assessment in the past, increasingly the need for more
than one piece of evidence for hazard assessment has become evi-
dent. This need is fundamental in both the AOP concept and the
AOP-informed IATA. Therefore, data integration strategies are
needed to integrate in silico, in chemico, in vitro, in vivo, and avail-
able epidemiological or clinical data which:
1. Allow for the combination of low-cost (sensitive) screening
assays with more sophisticated (specific) confirmatory assays.
2. Consider the incomplete coverage of one assay in the chemical
universe (applicability domain), severity classes or modes of
action.Table 2
Summary and examples of the different types of experimental testing approaches in AOP-
Approach Usage AOP
target
Example(s) of HT/HC compat
In chemico Indicate reactivity or
covalent interaction
with a biomolecule
MIE GSH (Schultz et al., 2005); dN
(Zhao et al. 2002)
In vitro (cellular) Confirm toxicity
pathway
Confirm the (absence
of) need for higher-
tier testing
Can be HT/HC
compatible
MIE,
KE
Cell lines, transactivation and
subcellular assays, e.g. HTS a
disruption (Cox et al., 2014;
Invertebrates Replace (vertebrate)
animal tests
MIE,
KE
C. elegans (Leung et al. 2008)
Fish or amphibian
embryos
Replace (adult
vertebrate) animal
tests
MIE,
KE
D. rerio embryos (Truong et a
Notes: GSH = reduced glutathione, dNTP = deoxyribonucleotide triphosphate, HT/HC = hi3. Compensate for the insufficient reliability of a single test.
4. Combine kinetic and exposure information, with (quantitative)
in vitro to in vivo extrapolation.
Testing and non-testing outcomes can be manually integrated
together to derive an outcome for specific regulatory purposes.
This is relatively straightforward for a simple linear AOP with
a limited number of KEs, such as that for skin sensitization
(OECD, 2012a,b). As more AOPs are developed, and KEs are
identified that cut across different AOPs into networks of inter-
linked AOPs, the complexity of data integration supporting an
IATA will increase. Manual integration of a myriad of KEs may
not be feasible to do. Moreover, some of the assay outcomes
or prediction models derived may require interpretation, a trans-
lation step to convert the raw test outcome into a form that
addresses the information need for the regulatory purpose under
consideration (see Weinberg, 1971 for a detailed discussion).
Note this interpretation step is not specific to IATA, but as the
complexity of IATA increases, more formalized systematic and
transparent translation approaches will be required. Integration
of many information sources can be addressed in different ways
from:
1. Battery approaches, i.e. all results are collected and then
interpreted.
2. Sequential/tiered approach, i.e. in a given sequence results
are collected stopping when sufficient information is avail-
able through to
3. Result-driven further testing, e.g. determination of next
most valuable test or branching of test strategies depend-
ing on previous test results (prioritization).
Integration of results derived from these information sources in
turn occurs on different levels, from the raw data level to the
summary (categorical) level where certain information is lost.
Examples of data integration approaches include:
1. Boolean AND/OR/NOT combinations of categorized results
(e.g. overall call is denoted as positive if any of the test out-
comes are positive).
2. Scoring approaches (e.g. various tests contributing to an
overall score).
3. Decision trees (typically sequential with branching).
4. Deterministic, i.e. a point of departure for assessments is
derived (e.g. lowest active concentration) possibly
combined with assessment factors to derive a threshold
value.informed IATAs.
ible assays Adverse outcome
TP adduct formation Unspecific (excess toxicity), genotoxicity/mutagenicity,
immunosuppression, skin sensitization
reporter cell assays,
ssays for endocrine
Murk et al., 2013)
Through targeting specific toxicity pathways, a wide
range of AOs can be targeted (Bhattacharya et al. 2011)
e.g. for endocrine disruption sexual development,
reproductive disorders. Many different endpoints are
possible through targeting specific toxicity pathways
e.g. Acute toxicity, developmental toxicity,
neurotoxicity, genotoxicity,
l., 2014) Acute and chronic fish toxicity, hepatoxicity
neurotoxicity, teratogenicity, endocrine disruption
(reviewed in Scholz, 2013; Scholz et al., 2013)
gh-throughput/high-content.
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different information leading typically to distributions of
probabilities/uncertainties.
6. Prediction based on machine learning (e.g. PCA, random
forest, multiple regression) applied to a training set of
compounds.
IATA does extend beyond hazard information and will often also
include kinetics and exposure data, which in turn augments the
complexity of the data integration approaches applied. At this
stage, no general guidance can be proposed, although it is envis-
aged that a learning-by-doing is necessary and the advantages
(and possible disadvantages) of formally integrated data will
emerge and can be resolved.4. Applicability of AOP-informed IATA for regulatory purposes
Any non-standard approach needs to be fit for purpose whether
it will be used for prioritization, hazard identification, classification
and labelling and/or risk assessment. This is true for IATA as a
whole, as well as the respective IATA elements themselves; the lat-
ter of which have already been discussed in the previous sections.
Specific criteria to define fitness for specific regulatory applications
have not been defined but guiding principles are being proposed.
Becker et al. (2014) outlined a scientific confidence framework first
proposed for HT/HC screening assays (Patlewicz et al., 2013) and
their prediction models (Cox et al., 2014) but adapted it to help
in the evaluation of AOPs for different purposes including IATA.
Specific guidance for the assessment of IATA is not currently
available but recent initiatives taken up by the OECD Task Force
for Hazard Assessment (TFHA) are aiming to develop general
principles for the evaluation and documentation of IATA using skin
sensitization as an initial case study (Worth and Patlewicz,
submitted). The initial principles proposed are framed by a clear
identification of the regulatory requirement as well as the applica-
bility domain of the IATA itself:
(a) Define the endpoint of regulatory concern being assessed.
(b) Define the purpose/application for which the IATA is
proposed.
(c) Describe the rationale, including mechanistic basis (e.g.
AOP), according to which the IATA is constructed.
(d) Describe the individual information sources constituting the
IATA.
(e) Characterize the predictive performance and applicability
domain of the IATA, or IATA subcomponent(s) that can be
expressed as a prediction model(s).
5. Examples of AOP-informed IATAs in regulatory decision-
making
There are many potential regulatory applications for IATA. In
this section, we highlight three case study examples, which target
different regulatory scenarios and hence are characterized by dif-
fering levels of scientific confidence.
5.1. Identification of chemicals disrupting estrogen, androgen, and
thyroid hormone pathways
Endocrine disruption, particularly disruption of estrogen,
androgen and thyroid pathways, is considered as an endpoint of
high regulatory concern, given the potential adverse impact on
human and environmental health, particularly sexual differentia-
tion, reproduction and population development. AOPs linked to
endocrine disruption of these three hormonal pathways representexamples where links between the MIE and KEs and the final AO
have been reasonably established (Ankley et al., 2005; Miller
et al., 2009; Volz et al., 2011). The OECD has already provided a
conceptual framework describing the assays that would be avail-
able to target the different MIE and KE for endocrine disruption
(OECD, 2012c). Recent suggestions for developing scientific criteria
for identification of an endocrine disrupting chemical (EDC) also
conform to the principle of providing evidence of causality
between mechanistic information (e.g. KEs) and AOs for endocrine
disruption (Munn and Goumenou, 2013). Principally there is no
single AOP for endocrine disruption. Depending on the targeted
hormonal pathway or whether it is applied in the environmental
or human health context, multiple AOPs could be defined. How-
ever, they share great commonalities at the different levels of bio-
logical complexity and are therefore described here (see Table 3).
In the US, the Endocrine Disruption Screening Program (EDSP)
was established in an effort to identify substances with the poten-
tial to interact with components of the endocrine system. The Pro-
gram comprises two Tiers; Tier 1 consists of a battery of in vitro
and in vivo assays that are intended to determine the potential of
a chemical to interact with the estrogen (E), androgen (A), or thy-
roid (T) hormone pathways whereas Tier 2 comprises multigener-
ational reproductive and developmental toxicity tests in several
species to determine whether a substance can cause adverse
effects resulting from effects on the E, A, or T pathways. In Tier 2,
the tests to be run are selected by a WoE evaluation of Tier 1
results. The Tier 1 battery itself is expensive, time consuming
and does not lend itself to the assessment of large numbers of
chemicals (each Tier 1 costs of the order of 1 million US dollars).
Furthermore, it still relies to a large extent on in vivo assays. Hence,
more cost-efficient processes relying on in silico (QSAR and Expert
Systems) and HT screening data for prioritizing large numbers of
chemicals for hazard assessment purposes are being developed
(Fig. S1, supplementary information outlines the use of the frame-
work for prioritizing substances for their potential E, A and T
effects). When coupled with exposure predictions (from ADME
and exposure models), such a combination of non-testing and
resource-efficient testing approaches could provide sufficient con-
fidence in prioritization decisions for subsequent testing require-
ments. The EDSP represents an opportunity where relevant HTS
assays can be mapped to associated AOPs that are already well
understood (e.g. Schmieder et al., 2003; Crofton and Zoeller,
2005) and where confidence in the HTS predictive power for higher
levels of the AOP are well established.
While the goal of the US EDSP and application of corresponding
HTS assays is clearly one of prioritization and directing of testing,
there is also scope to apply a tiered approach for defined testing
schemes such as required by European Union regulations. Sub-
stances with endocrine disrupting capacity are conditionally
exempted from exposure criteria, i.e. higher tier assays for these
compounds are required also at lower production volumes. Simi-
larly, Tier 1 in vivo assays to analyze the endocrine disruption
potential are required in environmental hazard assessment for
the regulation of pesticides, biocides and pharmaceuticals
(Scholz, 2013; Scholz et al., 2013). It is however, not yet clear
how the endocrine disrupting potency will be identified but HT
assays may provide a cost-effective and reliable approach.
HT screening assays for determination of interference with hor-
mone production, hormone receptor binding and activation are
currently available for a number of hormone pathways. Of these,
assays to target interference with the estrogen pathway seems to
be best developed with HTS methods for steroidogenesis and aro-
matase inhibition (Villeneuve et al., 2007; Vinggaard et al., 2000),
estrogen receptor (ER) binding and activation (Legler et al., 1999;
Tollefsen and Nilsen, 2008; Tollefsen et al., 2008) and in silico
(QSARs and docking models) for interaction with the ER
Table 3
Examples of MIEs and KEs relevant for different levels of the AOPs for endocrine disruption. Given the large number of assays available for the different MIEs, KEs, and AOs, only
selected examples are presented. For further assays descriptions refer to OECD (2012c).
AOP level
(MIE and KE not in
sequential order)
Description (examples) Level of biological
organization
Test/non test method examples
MIE1 Hormone receptor binding and activation Molecular level Receptor-ligand binding assays (Tollefsen and Nilsen, 2008); Transactiva-
tion assays (Legler et al., 1999);
QSARs for hormone receptor binding (Lo Piparo and Worth, 2010; Novic
and Vracko, 2010)
MIE2 Interference with hormone synthesis Molecular level Steroidogenesis in vitro (OECD TG 456);
In vitro assays for induction and inhibition of enzymes for TH metabolism
(Murk et al., 2013);
Zebrafish embryo assay for disruption of thyroid gland function (Raldua and
Babin, 2009)
KE 1 Cell proliferation Cellular MCF7 cell proliferation assay (Körner et al., 1998)
KE 2 Increased vitellogenin production Cellular In vitro fish hepatocyte vitellogenin production (Tollefsen et al., 2008)
KE3 Proliferation of uterus
Metamorphosis
Organ Uterotrophic assay (OECD TG 440)
Amphibian metamorphosis assay (OECD TG 231)
KE4 Vitellogenin induction, 2nd sex
characteristics, fecundity, gonad
development
Organ
Organism
Fish Reproductive Screening Assay (OECD TG 229)
AO Reproduction Population Reproductive toxicity studies
Fish full life cycle assays (TG 415, 443)
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exists for androgen signaling pathways, although the role of andro-
gen agonists or antagonists in endocrine disruption is not as well
developed. Nevertheless, assays such as a transcriptional activation
assay for the detection of the androgenic and anti-androgenic
activity of chemicals have been developed to support the assess-
ment of disruption of the androgen axis (Rostkowski et al., 2011).
HT assays for detecting thyroid receptor agonists and antagonists
also exist (Murk et al., 2013), however, the majority of thyroid dis-
ruptors act via a variety of MIEs that alter cellular TH signaling
pathways via modulation of the TH levels. Thus, for thyroid dis-
rupting compounds the most relevant KE with respect to AO is
the reduction of thyroid hormone synthesis and homeostasis
(Capen, 1997; Crofton, 2008). Appropriate thyroid hormone-rele-
vant assays are missing for many of the targets, and development
of appropriate assays that cover relevant MIEs and KEs are strongly
needed (Murk et al., 2013). As an interim approach, TR transcrip-
tion assays such as ToxCast and Tox21-TR assays can be applied.
Assays of fish embryos targeting reduced T4-levels (Thienpont
et al., 2011; Opitz et al., 2012) can be employed to identify
goitrogens. Despite the remaining high uncertainty for thyroid
hormone disruption, a significant reduction of higher tier testing
could be achieved by including exposure modelling into the
screening approach. Wambaugh et al. (2013) have developed a
high-throughput exposure model that uses data on production
and use of chemicals, in combination with a Bayesian statistical
approach to describe the degree of uncertainty, to provide expo-
sure estimates for thousands of chemicals. Combining this with
hazard data allows for a rapid estimate of margins of exposure
and prioritization of further testing using both exposure and haz-
ard data. Whilst the IATA framework has been illustrated for prior-
itization per se, it could be refined for other purposes such as
classification and labelling, or hazard assessment both of which
would be pertinent for registration of chemicals in Europe.
5.2. Skin sensitization
Skin sensitization has been well studied over many decades.
The chemical and biological pathway driving the induction and
elicitation of allergic contact dermatitis is relatively well under-
stood (see Lepoittevin et al., 1997; Smith Pease, 2003; Adler
et al., 2011) and this knowledge has helped shape the development
of alternative non-animal test methods. Most recently theknowledge has been structured and documented in an AOP con-
struct and published by the OECD (2012a,b). The OECD documen-
tation for this AOP summarizes the scientific evidence and assesses
the overall WoE supporting the AOP. There is strong evidence for
the qualitative sequence of events from the MIE to AO. Indeed
empirical evidence from various elements of the AOP has value
in assessing the potential of a chemical to be a skin sensitizer
but, with few exceptions, it is insufficient to predict the relative
potency of a chemical. As such, animal methods, in particular the
Local Lymph Node Assay (LLNA) are at present still needed to pro-
vide a quantitative measure of relative sensitizing potency, which
is critical for risk assessment applications.
In order for the AOP for skin sensitization to be applied in prac-
tice, available test/non test approaches that characterize each of
the KEs need to be mapped to the AOP. This mapping provides a
perspective of what practical testing/non testing strategies could
be derived as IATA. For skin sensitization, there has been consider-
able progress in developing specific test methods that target MIEs
and many of the KEs relevant for the AO (see Table 4 for examples
of appropriate assays).
A specific framework for the assessment of skin sensitization
potential was adapted from Fig. 1 (shown in Fig. S2 of the supple-
mentary information). In applying the framework, two outcomes
can be envisaged – either the evaluation of the model/assay out-
comes will result in a consistent profile enabling an assessment
of skin sensitization hazard to be made (i.e. the substance is
(not) a skin sensitizer with high confidence) or the outcomes are
insufficient to conclude with any great certainty that the substance
is (not) a skin sensitizer. The latter could be due to inadequacies in
the model/assay domains of applicability either on the basis of the
underlying training sets or due to technical limitations in the
assays themselves (volatility, solubility, metabolic competence).
These insufficiencies however inform the development or refine-
ment of new test assays or refinement/extension of the in silico
models. Any new information then generated can be passed back
to refine and improve the original AOP for sensitization. A more
detailed example for this IATA for skin sensitization has been dis-
cussed in a separate manuscript (see Patlewicz et al., 2014).
5.3. AChE inhibition leading to lethality
Organophosphate and carbamate insecticides, which are widely
used for agricultural and residential purposes, have frequently
Table 4
A summary of in silico and experimental testing approaches targeting MIEs and KEs of skin sensitization.
AOP level Description Level of biological
organization
Test/non test method
Dermal exposure Dermal metabolism, epidermal
disposition
Chemical structure and
properties
(Q)SARs
MIE Covalent binding between electrophile
and skin protein
Molecular level DRPA (Gerberick et al., 2004, 2007), GSH depletion assay (Schultz et al.,
2005), QSARs/read-across
KE 1 Activation of inflammatory cytokines Cellular response KeratinoSens™ (Emter et al., 2010, 2013), read-across
KE 2 Maturation and mobilization of
dendritic cells
Cellular response MUSST (Python et al., 2007), h-CLAT (Sakaguchi et al., 2007), read-
across
KE 3 T-cell proliferation Organ response LLNA (OECD Test Guideline (TG) 429), QMM, read-across
Adverse outcome (AO) Allergic contact dermatitis Organism response GPMT (OECD TG 406); HRIPT
Notes: DRPA = Direct peptide reactivity assay, GSH = Reduced glutathione, MUSST = Myeloid U937 skin sensitization test, h-CLAT = Human cell line activation test, LLNA = -
Mouse local lymph node assay, QMM = Quantitative mechanistic model, GPMT = Guinea pig maximization test, HRIPT = Human repeat insult patch test.
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brates to vertebrates and mammals (McHenery et al., 1997; Fulton
and Key, 2001). The toxicity of these compounds is mainly due to
the selective inhibition of acetylcholinesterase (AChE), leading to
accumulation of acetylcholine (ACh) in the synaptic cleft, subse-
quent overstimulation, and the disruption of nerve impulses
ultimately leading to ataxia, central respiratory paralysis, seizures,
coma and death (Costa, 2006; Bradbury et al., 2008). The well-
developed knowledge on how these chemicals cause lethality has
led to the development of an AOP for acetylcholinesterase inhibi-
tion leading to acute mortality (Russom et al., 2014). This AOP is
characterized by a clear mechanistic understanding of the MIE,
KEs and AOs (Table 5) for a number of species (Russom et al.,
2014). The available information on relevant chemical structures,
the overall weight of evidence and the broad taxonomic applicabil-
ity domain of this AOP are of particular value to inform and provide
input to IATAs, particularly for cross-species extrapolations.
Since Acetylcholine esterase (AchE) inhibition is a well-
established AOP, it can support a variety of regulatory uses. The
WoE supporting this AOP is strong (Russom et al., 2014), and there
is extensive toxicity data for a number of chemicals in a variety of
species that is consistent with mechanistic knowledge assembled
in the AOP (http://www.epa.gov/ecotox/). Information from
in vitro results could potentially be used under certain circum-
stances, but the use of in vitro AChE inhibition alone may not be
sufficient (Knudsen et al., 2011) possibly due to lack of these assays
accounting for bioactivation of certain chemicals such as Diazinon
by metabolism (Aylward and Hays, 2011) or mitigation of effects
by metabolic degradation such as observed for malathion (de
Bruijn and Hermens, 1993). In silico approaches might be sufficient
for some uses (Fukuto, 1990; El Yazal et al., 2001; Wong et al.,
2012), but should be used with caution particularly in cases where
metabolic activation is required (de Bruijn and Hermens, 1993).
Extensive in vivo data exist with reasonable concordance seen
between sequence similarity among AChE enzymes and in vivo
activity across non-vertebrate species (Russom et al., 2014). For
animals, including humans, determination of AchE inhibition in
both the central and peripheral nervous systems are considered
crucial for a thorough evaluation of potential hazard (http://
www.epa.gov/pesticides/trac/science/cholin.pdf). However, blood
cholinesterase inhibition is accepted as a surrogate parameter in
humans, when data for AchE inhibition in peripheral and central
nervous system are not available. Recommendations on surrogate
parameters in wildlife have currently not been developed suffi-
ciently to support a WoE approach to identify potential hazard.
To illustrate how this AOP could be used in IATA, consider the
classification of a pesticide known to act via AChE inhibition as a
potential application. A particular concern in this case is the bio-
logical impact on non-target organisms (see Fig. S3 in supplemen-
tary information). If this is a crop use that is expected to result inminimal exposure through either application or ingestion, the spe-
cies of concern might be restricted to non-target organisms that
would be exposed during the application or via interactions with
the treated crops and possibly aquatic organisms from runoff fol-
lowing application. Demonstration of low level of exposure in com-
bination with low sensitivity for AchE in vertebrates, would be
expected to limit potential hazards to non-target invertebrates. If
toxicity data from the target species (e.g. insects for use of insecti-
cides) exist, hazard assessment could be facilitated by sequence
alignments to predict cross-species susceptibility to non-target
species where exposure is considered relevant (Lalone et al.,
2013; Russom et al., 2014). Documentation of potential risk sce-
narios (e.g. small margin of safety between exposure and potential
effects) based on the non-testing approaches proposed herein, may
lead to a decision to generate additional testing data using in vivo
studies with the appropriate species or relevant surrogate species
in cases where testing is not feasible (e.g. endangered species, lack
of appropriate laboratory strains etc.).
This hypothetical case study illustrates how a well-defined AOP
could be used for certain regulatory purposes independent of
chemical specific information at the intermediate key events. The
weight of evidence incorporates over 50 years of research includ-
ing basic biochemistry as well as toxicology. Given the strong sup-
port and conservation of the AOP across taxa, a wealth of
toxicological data at the organism level can be leveraged for the
decision at hand. This allows the use of in silico predictions for
cross-species extrapolations in combination with use of data from
experimentally tractable species to limit the need for additional
studies to characterize intermediate events of well-developed
AOPs. If this were not the case, other approaches such as in vitro
screening and in vivo measurement of intermediate KE (Fig. S3 in
supplementary information) would likely be required to safeguard
against adversely impacting non-target species.6. Implications for Integrated Toxicology and Regulatory
Applications
Development and application of AOP-informed IATA represents
a new way to evaluate and generate information to meet different
regulatory purposes. A conceptual framework for applying IATA
has been proposed that considers existing information (from a
hazard and exposure perspective) in the context of an AOP to make
an informed decision based on the regulatory context. Frameworks
to characterize the scientific confidence of an AOP that are required
to meet different regulatory needs are in development (Becker
et al., 2014; Patlewicz et al., submitted; Perkins et al., submitted).
These will shape the structure of the IATA and its elements in
terms of the test methods and non-testing approaches. Establish-
ing scientific confidence is critical for both the elements making
Table 5
A summary of in silico and experimental testing approaches relevant for different levels of the AOP – Acetylcholine esterase (AchE) inhibition leading to lethality (Russom et al.,
2014). References represent examples only. See Russom et al. (2014) for a more extensive review of the literature supporting this AOP.
AOP
level
Description Level of
biological
organization
Test/non test method
MIE Inhibition of AchE activity. Inhibition caused by
non-reversible or reversible inhibition
Molecular level QSARs/read-across Inhibition of AchE activity (in vitro) (Garcia-Reyero et al., 2014b;
Holth and Tollefsen, 2012)
KE1 Accumulation of acetylcholine (ACh) in the
synaptic cleft
Cellular level No direct test-method available; biological plausibility well established; many studies
linking MIE with downstream KEs & AOs across a variety of species (Bianco et al., 2013);
Brain ACh levels can serve as a surrogate biomarker for associated KEs (Kobayashi et al.,
1985)
KE2 Excitatory responses in muscle and brain Organ level Electrophysiology in isolated neurons (Oyama et al., 1989); Contractile response in
muscle (Kobayash et al., 1994); Altered response in brain (biological plausibility well
established)
AO Neurotoxic symptomology (increased
respiration, bradycardia, seizures) leading to
death
Organism Respiratory/cardiovascular responses (McKim et al., 1987); Altered photomotor or
locomotor response (Kokel et al. 2010; Irons et al. 2010; Garcia-Reyero et al. 2014b);
AO Population decline Population Inferred based on measured effects on mortality (Barata et al., 2004) and feeding
behavior (Hunt et al., 1991)
Fig. 2. Relationship between strength of evidence (reliability, relevance and concordance etc.) for the IATA supporting the AO of regulatory concern and the importance of the
regulatory decision to be made. The figure shows the possible combination of AOP based information and available data, and how the use of one could be strengthened by the
other. The color of the cells represent the amount of additional information from other sources needed for a decision (the darker the color, the more additional information is
needed to reach a decision with confidence). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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been described in detail to illustrate how the conceptual frame-
work proposed in Section 1 can be adapted to meet different
regulatory purposes (e.g. prioritization, hazard assessment, classi-
fication and labelling and other applications such as cross-species
extrapolations).
The EDC example shows how a battery of AOPs and associated
HT assays can be used in a prioritization scenario. This addresses
the first 4 principles for IATA development and application as out-
lined in Section 4. The skin sensitization example, which is aimed
at addressing hazard assessment, arguably addresses all 5 princi-
ples. The AchE inhibition example illustrates how an established
AOP can be used for classification and labelling in certain regula-
tory contexts despite a lack of properly developed testing and
non-testing methods spanning the full AOP continuum. In the reg-
ulatory context considered for that example, the need for explicit
tests of intermediate KEs is avoided by the wealth of data available.
A well-developed AOP and by demonstration of phylogenetically-
conserved MIEs across taxa enable identification of susceptible
species being particularly relevant or tractable to cost-efficient
in vivo testing (e.g. invertebrates). Clearly the degree to which
these principles need to be characterized can and will differ based
on the level of uncertainty that can be tolerated for the regulatory
purpose under consideration. Scientific confidence of the AOP and
its associated IATA will be strongest where there is a close link
between the MIE and KEs to the AO.
There is a desire to exploit in silico and HTS testing tools to pop-
ulate an IATA. One starting point for such AOP-informed IATAs
could be to apply in silico methods or HT approaches for providing
information about the MIE to determine what data if any wouldneed to be generated for different KEs or the AO for a given chem-
ical. The stronger the evidence coming from non-testing or alterna-
tive testing approaches, the less additional information would, in
theory, need to be generated for a given decision. Thus, a moderate
level of confidence might be sufficient for a prioritization purpose,
but in order to make a decision related to hazard and risk assess-
ment, assays or a combination of assays closely linked to the MIE
and with high predictivity of the AO may be required (Fig. 2.).
Additional information on one or more KEs along the pathway gen-
erated from in vitro, in chemico or HT/HC assays would serve to pro-
vide increasing confidence for a given decision.
Of course implicit in such a confidence determination, is the
WoE evaluation of the AOP itself. The OECD AOP guidance entails
completing a template, using evolved and tailored Bradford Hill
(BH) considerations, in which each KEs and KE relationships (KERs)
in an AOP are evaluated and are scored as high, moderate and low
(OECD, 2013). The outcomes of these WoE determinations for the
KEs and KERs of an AOP help in making a determination of whether
different decisions are feasible based on the outcomes of MIEs or
other KEs and the extent to which they are predictive of the AO.
The case studies presented could in theory be applied in prac-
tice now, although the number of well-developed AOPs is currently
limiting the practical applicability for larger scale regulatory
deployment. Furthermore, consideration needs to be given to the
analytical validation of testing and non-testing approaches in order
to better characterize their applicability domain i.e. the types of
chemicals that can be reliably assessed. A detailed description of
AOPs of regulatory relevance and the establishment of qualitative
and quantitative links between MIEs, KEs and AOs will additionally
help foster application for different regulatory decisions. While
638 K.E. Tollefsen et al. / Regulatory Toxicology and Pharmacology 70 (2014) 629–640qualitative links are already established for a number of the AOPs
so far developed and supported by visualization and description
tools such as the AOP Knowledge Base (https://aopkb.org), appro-
priate quantitative approaches for confidence evaluation by WoE
assessments of KERs are currently being critically assessed
(Barton-Maclaren et al., in preparation). Recent initiatives to pro-
vide quantitative assessment of the role of MIE and KE proximity
to the AO for the confidence of predictions to regulatory-relevant
endpoints will likely also assist in developing pragmatic tools for
IATA development. Additional improvements of IATAs by including
toxicokinetics and reverse dosimetry into extrapolations to regula-
tory-relevant endpoints would further increase the applicability of
IATAs for practical use.
Although not necessarily applicable to the case studies high-
lighted here, many of the AOPs in development have been data-
rich and based on historical in vivo data. Thus the body of evidence
to justify the essentiality of KEs and the linkages has facilitated dif-
ferent use scenarios including risk assessment where the KEs prox-
imal to the AO are better defined. Going forward, the challenges
foreseen will be to identify the data gaps and assay needs, to inte-
grate different AOPs together to provide a more holistic assessment
of likely effects. The latter is a major issue as an AOP by its nature
assumes that adversity can be described by a relevant assembly of
MIEs and KEs, whereas the question remains of how many AOPs
need to be integrated into IATA to assure that there is no important
hazard or adversity overlooked.Conflict of interest
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